Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
| Заболевание | Lung Carcinoma |
|---|---|
| Фаза | Не применимо |
| Спонсор | M.D. Anderson Cancer Center |
| Статус | Идёт, набор закрыт |
| Участники | 135 участн. |
| Вмешательство | Nicotine Replacement |
| Дата начала | 7.03.2022 |
| Дата завершения | 17.10.2025 |
| Публикация результатов | 5.08.2026 |
Кратко
This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching smokers at high risk for lung cancer to electronic cigarettes. This research also may help inform the Food and Drug Administration (FDA) how best to regulate e-cigarettes with the goal of improving public health.
Combustible Cigarettes Per Day
| Electronic Cigarettes Arm | 15.36 ± 8.93 cigarettes per day |
|---|---|
| Electronic Cigarettes Arm | 7.52 ± 7.54 cigarettes per day |
Открыть в BENITIONS Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tum — National Cancer Institute (NCI)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients W — National Cancer Institute (NCI)
- A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients W — AstraZeneca
- Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therap — National Cancer Institute (NCI)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With — National Cancer Institute (NCI)
- Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Pos — National Cancer Institute (NCI)